CD274 and cancer: Presently, the FDA has approved PD-1/PD-L1 inhibitors for the treatment of 9 cancer types (https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications) with immune checkpoint inhibitor monotherapy.